Skip to content
OpenCapital
Get started

Kura Oncology KURA Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——
Ethos Technologies, Inc. logo
Ethos Technologies, Inc. LIFE
——

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's available for sale securities debt securities current?
Kura Oncology (KURA) reported available for sale securities debt securities current of $541.74M in Q1 2026.
How has Kura Oncology's available for sale securities debt securities current changed year-over-year?
Kura Oncology's available for sale securities debt securities current decreased by 10.7% year-over-year, from $606.92M to $541.74M.
What is the long-term trend for Kura Oncology's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Kura Oncology's available for sale securities debt securities current has grown at a 11.0% compound annual growth rate (CAGR), from $307.83M to $518.14M.